Publications

Complete list of publications can be found here.

 


2018

Boettcher, M., Tian, R., Blau, J.A., Markegard, E., Wagner, R.T., Wu, D., Mo, X., Biton, A., Zaitlen, N., Fu, H., McCormick, F., Kampmann, M., McManus, M.T. 2018. Dual gene activation and knockout screen reveals directional dependencies in genetic networks. Nature Biotechnology doi: 10.1038/nbt.4062. [Epub ahead of print]


2017

Kitagawa, M., Liao, P.J., Lee, K.H., Wong, J., Shang, S.C., Minami, N., Sampetrean, O., Saya, H., Lingyun, D., Prabhu, N., Diam, G.K., Sobota, R., Larsson, A., Nordlund, P., McCormick, F., Ghosh, S., Epstein, D.M., Dymock, B.W., Lee, S.H. 2017. Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality. Nature Communications 8(1):2200. doi: 10.1038/s41467-017-02287-5.

Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, McCormick F, McManus MT. 2017 Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551:247-250

Waters, A.M., Ozkan-Dagliyan, I., Vaseva, A.V., Fer, N., Strathern, L.A., Hobbs, G.A., Tessier-Cloutier, B., Gillette, W.K., Bagni, R., Whiteley, G.R., Hartley, J.L., McCormick, F., Cox, A.D., Houghton, P.J., Huntsman, D.G., Philips, M.R., Der, C.J. 2017. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling 10 (498).  doi: 10.1126/scisignal.aao3332

Tetsu O, McCormick F. 2017 ETS-targeted therapy: can it substitute for MEK inhibitors? Clinical and Translational Medicine 6:16

Simanshu DK, Nissley DV, McCormick F. 2017 RAS proteins and their regulators in human disease. Cell 170:17-33

Novotny CJ, Hamilton GL, McCormick F, Shokat KM. 2017 Farnesyltransferase-mediated delivery of a covalent inhibitor overcomes alternative prenylation to mislocalize K-Ras. ACS Chemical Biology 12:1956-1962

Stephens RM, Yi M, Kessing B, Nissley DV, McCormick F. 2017 Tumor RAS gene expression levels are influenced by the mutational status of RAS genes and both upstream and downstream RAS pathway genes. Cancer Informatics 16:1-10

Boettcher M, Tian R, Blau J, Markegard E, Wu D, Biton A, Zaitlen N, McCormick F, Kampmann M, McManus MT. 2017 Decoding directional genetic dependencies through orthogonal CRISPR/Cas screens. bioRxiv 120170

Wang SJ, Asthana S, van Zante A, Heaton CM, Phuchareon J, Stein L, Higuchi S, Kishimoto K, Chiu CY, Olshen AB, McCormick F, Tetsu O.  2017 Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient. Oral Oncology 69:1-10


2016

Dharmaiah S, Bindu L, Tran TH, Gillette WK, Frank PH,   Ghirlando R, et al. 2016 Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ. Proc Natl Acad Sci USA 113(44):E6766-E6775. Epub 2016 Oct 17.

Gerhard DS, Clemons PA, Shamji AF, Hon C, Wagner BK, Schreiber SL, et al. 2016 Transforming big data into cancer-relevant insight: an initial, multi-tier approach to assess reproducibility and relevanceMol Cancer Res. 14(8):675-82. doi: 10.1158/1541-7786.MCR-16-0090. Epub 2016 Jul 11.

Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K. 2016 The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc Natl Acad Sci U S A. Jun 16. pii: 201607298. [Epub ahead of print]

Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. 2016. Drug resistance to EGFR Inhibitors in lung cancer. Chemotherapy. 61(5):223-235.  doi: 10.1159/000443368. Epub 2016 Feb 25.

Stevenson DA, Schill L, Schoyer L, Andresen BS, Bakker A, Bayrak-Toydemir P, et al. 2016. The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway. Am J Med Genet A. 170(8):1959-66. doi: 10.1002/ajmg.a.37723. Epub 2016 May 7.

McCormick F. 2016. K-Ras protein as a drug target. J Mol Med (Berl). 94(3):253-8. doi: 10.1007/s00109-016-1382-7. Epub 2016 Mar 9.


2015

McCormick F. 2015 The potential of targeting Ras proteins in lung cancer. Expert Opin Ther Targets. 19(4):451-4. doi: 10.1517/14728222.2014.1000304. Epub 2015 Jan 6.

Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S. 2015 Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 5(2):154-67. doi: 10.1158/2159-8290.CD-14-0552. Epub 2014 Dec 12.

McCormick, F. 2015. KRAS as a therapeutic target. Clin Cancer Res 21(8):1797-801. doi: 10.1158/1078-0432.CCR-14-2662.

Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, Ruggero D, McCormick F. 2015. Enhanced MET translation and signaling sustains K-Ras driven proliferation under anchorage-independent growth conditions. Cancer Res 75:2851-62 doi: 10.1158/0008-5472.CAN-14-1623. Epub 2015 May 14

Nan X, Tamgüney, TM, Collisson EA, Lin LJ, Pitt C, Galeas J, Lewis S, Gray JW, McCormick F, Chu S. 2015. Ras-GTP dimers activate the mitogen-activated protein kinase (MAPK) pathway. Proc Natl Acad Sci U S A 112:7996-8001 doi: 10.1073/pnas.1509123112. Epub 2015 Jun 16.

Phuchareon J, McCormick F, Eisele DW, Tetsu O. 2015. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A 112:E3855-63 doi: 10.1073/pnas.1510733112. Epub 2015 Jul 6.

Tetsu O, Eisele DW, McCormick F. 2015. Resistance to EGFR-targeted  by Ets-1 inactivation. Cell Cycle 14:3211-2. doi: 10.1080/15384101.2015.1086200. 

Gillette WK, Esposito D, Abreu Blanco M, Alexander P, Bindu L, Bittner C, et al. 2015. Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions. Sci Rep. 5:15916. doi: 10.1038/srep15916.

Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. 2015. K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell 163 :1237-51. doi: 10.1016/j.cell.2015.10.041.

Tetsu O, Phuchareon J, Eisele DW, Hangauer MJMcCormick F. 2015. AKT inactivation causes persistent drug tolerance to EGFR inhibitors. Pharmacol Res. 102:132-7. doi: 10.1016/j.phrs.2015.09.022. Epub 2015 Oct 22.


2014

Phuchareon J, Overdevest JB, McCormick F, Eisele DW, van Zante A, Tetsu O. 2014 Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significance. Transl Oncol. 7(6):780-7. doi: 10.1016/j.tranon.2014.10.003.
 

Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F. 2014 Social interactomes for enabling research communities. Cancer Discov. 4(11):1265-8. doi: 10.1158/2159-8290.CD-14-0774.

Phuchareon J, van Zante A, Overdevest JB, McCormick F, Eisele DW, Tetsu O. 2014 c-Kit expression is rate-limiting for stem cell factor-mediated disease progression in adenoid cystic carcinoma of the salivary glands. Transl Oncol. 7(5):537-45. doi: 10.1016/j.tranon.2014.07.006. eCollection 2014.

Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, et al. 2014 Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 8(4):1037-48. doi: 10.1016/j.celrep.2014.07.010. Epub 2014 Aug 7.

Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, et al. 2014. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One 9(2):e87220. doi: 10.1371/journal.pone.0087220. eCollection 2014.

Salt MB, Bandyopadhyay S, McCormick F.  2014. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov 4(2):186-99. doi: 10.1158/2159-8290.CD-13-0520. Epub 2013 Dec 3.

Stephen AG, Esposito D, Bagni RK, McCormick, F. 2014. Dragging Ras back in the ring. Cancer Cell 25(3):272-81. doi: 10.1016/j.ccr.2014.02.017.

Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, et al. 2014. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res 74(8):2238-45. doi: 10.1158/0008-5472.CAN-13-1065-T. Epub 2014 Feb 12.

Holderfield M, Deuker M, McCormick F, McMahon M.  2014. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nature Rev Cancer 14(7):455-67. doi: 10.1038/nrc3760.

Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, et al. 2014. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov 4(10):1182-97. doi: 10.1158/2159-8290.CD-13-0900. Epub 2014 Aug 6.

Thai M, Graham NA, Braas D, Nehil M, Komisopoulou E, Kurdistani SK, McCormick F, Graeber TG, Christofk HR 2014. Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab 19(4):694-701. doi: 10.1016/j.cmet.2014.03.009.

 


2013

Young A, Lou D, McCormick F. 2013. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 3(1):112-23. doi: 10.1158/2159-8290.CD-12-0231. Epub 2012 Oct 25.

Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, et al.  2013.  RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.  Cancer Cell 23(5):594-602. doi: 10.1016/j.ccr.2013.03.033.

Lyons J, Bastian BC, McCormick, F.  2013.  MC1R and cAMP signaling inhibit cdc25B and delay cell cycle progression in melanoma cells.  Proc Natl Acad Sci USA 110(34):13845-50. doi: 10.1073/pnas.1201917110. Epub 2013 Aug 1.

Nan X, Collisson EA, Lewis S, Huang J, Tamguney TM, Liphardt JT, McCormick F, Gray JW, Chu S. 2013. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci USA 110(46):18519-24. doi: 10.1073/pnas.1318188110. Epub 2013 Oct 24.

Nehil M, Paquette J, Tokuyasu T, McCormick F.  2014. High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphoring 3A.  Oncogene 33(44):5151-62. doi: 10.1038/onc.2013.459. Epub 2013 Nov 11.

Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, et al.  2013. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24(4):450-65. doi: 10.1016/j.ccr.2013.08.020. Epub 2013 Oct 3.

Yuan TL, McCormick F.  2013. Killing tumors by keeping ras and PI3’ kinase apart. Cancer Cell 24(5):562-3. doi: 10.1016/j.ccr.2013.10.015.

 


2012

Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, et al. 2012. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 7(5):e37431. doi: 10.1371/journal.pone.0037431. Epub 2012 May 25.

Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F. 2012. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev 26(13):1421-6. doi: 10.1101/gad.190876.112.

 


2011

Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, et al.  2011. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet 157C(2):136-46. doi: 10.1002/ajmg.c.30294. Epub 2011 Apr 14.

McCormick F. 2011. Cancer therapy based on oncogene addiction. J Surg Oncol 103(6):464-7. doi: 10.1002/jso.21749.

McCormick F. 2011. Mutant onco-proteins as drug targets: successes, failures, and future prospects. Curr Opin Genet Dev  21(1):29-33. doi: 10.1016/j.gde.2010.12.002. Epub 2011 Jan 12.

Gysin S, Salt M, Young A, McCormick F. 2011. Therapeutic strategies for targeting ras proteins. Genes & Cancer 2(3):359-72. doi: 10.1177/1947601911412376.